Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Entrectinib
Synonyms
Therapy Description

Rozlytrek (entrectinib) inhibits the activity of TrkA/B/C, Ros1 fusion proteins, and Alk, which leads to induction of apoptosis and inhibition of proliferation in cells expressing these kinases (PMID: 27003761). Rozlytrek (entrectinib) is FDA approved for use in patients with ROS1 positive non-small cell lung cancer and in adult and pediatric (12 years and older) patients with solid tumors harboring NRTRK fusions without known acquired resistance mutations (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Entrectinib Rozlytrek RXDX-101 ALK Inhibitor 28 ROS1 Inhibitor 19 Trk Receptor Inhibitor (Pan) 29 Rozlytrek (entrectinib) inhibits the activity of TrkA/B/C, Ros1 fusion proteins, and Alk, which leads to induction of apoptosis and inhibition of proliferation in cells expressing these kinases (PMID: 27003761). Rozlytrek (entrectinib) is FDA approved for use in patients with ROS1 positive non-small cell lung cancer and in adult and pediatric (12 years and older) patients with solid tumors harboring NTRK fusions without known acquired resistance mutations (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NTRK1 fusion salivary gland cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with NTRK1 fusion-positive salivary gland tumors with distant metastasis (NCCN.org). detail...
EML4 - NTRK3 Advanced Solid Tumor predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a Phase Ib/II trial (STARTRK-NG), a patient with an advanced solid tumor harboring EML4-NTRK3 demonstrated a partial response when treated with Rozlytrek (entrectinib) (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 107-107; NCT02650401). detail...
EML4 - NTRK3 Advanced Solid Tumor predicted - sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, Rozlytrek (entrectinib) inhibited growth of transformed cells expressing EML4-NTRK3 in culture (PMID: 30279230). 30279230
EML4 - ALK ALK I1171N lung non-small cell carcinoma resistant Entrectinib Preclinical - Patient cell culture Actionable In a preclinical study, patient-derived non-small cell lung cancer cells harboring EML4-ALK with ALK I1171N were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - NTRK3 lung non-small cell carcinoma predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a Phase II trial (TRIDENT-1), a patient with metastatic non-small cell lung cancer harboring EML4-NTRK3 achieved a partial response during 12 months of treatment with Rozlytrek (entrectinib) (PMID: 34625502; NCT03093116). 34625502
EML4 - NTRK3 thyroid gland papillary carcinoma predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a clinical case study, a patient with papillary thyroid carcinoma harboring EML4-NTRK3 demonstrated a 69.7% decrease in disease burden after 34 cycles of treatment with Rozlytrek (entrectinib) (PMID: 32457407). 32457407
NTRK2 fusion thyroid gland Hurthle cell carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with thyroid Hurthle cell carcinoma harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK I1171N ALK L1198H Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1198H were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK1 fusion colon cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic colon cancer patients with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion thyroid gland follicular carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion anaplastic astrocytoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic astrocytoma (NCCN.org). detail...
EML4 - ALK ALK F1174I Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174I were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK C1156Y Advanced Solid Tumor sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Rozlytrek (entrectinib), resulting in anti-proliferative activity (PMID: 26939704). 26939704
EML4 - ALK ALK C1156Y Advanced Solid Tumor sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, Rozlytrek (entrectinib) inhibited viability of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 33627640). 33627640
EML4 - ALK ALK I1171N ALK F1174L Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and F1174L were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK1 rearrange sarcoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a standard treatment for patients with advanced sarcomas harboring NTRK rearrangement (PMID: 34303806; ESMO.org). detail... 34303806
EML4 - ALK ALK L1196Q Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196Q were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK1 fusion gallbladder cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic gallbladder cancer harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK F1174V Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174V were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK L1198F ALK G1202R Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F and G1202R were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
ALK positive neuroblastoma sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in partial response in a patient with ALK-positive neuroblastoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)). detail...
EML4 - ALK ALK I1171T Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171T were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK D1203N Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK D1203N were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK1 fusion glioblastoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent glioblastoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion thyroid gland anaplastic carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with metastatic thyroid gland anaplastic carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion pancreatic adenocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced or metastatic pancreatic adenocarcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion small intestine adenocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a subsequent-line therapy for patients with advanced or metastatic small bowel adenocarcinoma with an NTRK fusion and no satisfactory alternative treatments (NCCN.org). detail...
NTRK1 fusion ampulla of Vater adenocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line therapy when the performance score is poor or as subsequent therapy for metastatic ampullary adenocarcinoma patients harboring NTRK fusions (NCCN.org). detail...
NTRK1 fusion small intestine adenocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a subsequent-line therapy for patients with advanced or metastatic small bowel adenocarcinoma with an NTRK fusion and no satisfactory alternative treatments (NCCN.org). detail...
NTRK1 fusion differentiated thyroid gland carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for adult or pediatric patients 12 years or older with metastatic or unresectable differentiated thyroid gland carcinoma harboring NTRK fusions that have progressed on prior therapies (PMID: 31549998, PMID: 35491008; ESMO.org). detail... 35491008 31549998
ROS1 positive lung non-small cell carcinoma sensitive Entrectinib FDA approved Actionable In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 77% (41/53), a median duration of response of 25 months in patients with ROS1 fusion positive non-small cell lung cancer, with median progression-free survival of 26 and 14 months for patients without (n=30) and with (n=23) CNS disease, respectively (Cancer Res 2019;79(13 Suppl):Abstract nr CT192; NCT02097810; NCT02568267). detail... detail...
NTRK1 fusion gastroesophageal junction adenocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastroesophageal junction cancer with an NTRK fusion (NCCN.org). detail...
NTRK2 fusion low grade glioma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent or progressive low grade glioma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion pancreatic adenocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced or metastatic pancreatic adenocarcinoma harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK I1171N ALK L1198F Advanced Solid Tumor predicted - resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1198F demonstrated resistance to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK2 fusion endometrial carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a second-line therapy for patients with endometrial carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion hepatocellular carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion thyroid gland papillary carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK T1151K Advanced Solid Tumor sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, Rozlytrek (entrectinib) inhibited viability of transformed cells expressing EML4-ALK with ALK T1151K in culture (PMID: 33627640). 33627640
NTRK1 fusion low grade glioma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent or progressive low grade glioma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 rearrange sarcoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a standard treatment for patients with advanced sarcomas harboring NTRK rearrangement (PMID: 34303806; ESMO.org). detail... 34303806
NTRK1 fusion endometrial carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a second-line therapy for patients with endometrial carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion vulva squamous cell carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced or metastatic vulvar squamous cell carcinoma harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK F1245V Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK F1245V were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK I1171N ALK G1269A Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and G1269A were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK2 fusion colon cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic colon cancer patients with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion thyroid gland Hurthle cell carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with thyroid Hurthle cell carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion sarcoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is in guidelines for patients with soft tissue sarcoma with non-specific histology and an NTRK fusion (NCCN.org). detail...
NTRK2 fusion breast cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) therapy is included in guidelines for patients with recurrent or metastatic breast cancer harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK G1202R Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK G1202R Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to Rozlytrek (entrectinib) in culture (PMID: 26939704). 26939704
NTRK1 fusion cervical cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line therapy for patients with recurrent or metastatic cervical cancer harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK L1196M ALK G1202R Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and G1202R were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK1 fusion ovarian cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as systemic therapy for patients with recurrent ovarian cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion rectum cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic rectal cancer patients with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion vulva squamous cell carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced or metastatic vulvar squamous cell carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion gastrointestinal stromal tumor sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced/metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (PMID: 34560242; ESMO.org). detail... 34560242
NTRK1 fusion gastrointestinal stromal tumor sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with unresectable gastrointestinal stromal tumor (GIST) harboring NTRK fusions (NCCN.org). detail...
ALK F1245V neuroblastoma predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in a partial response that lasted 8.3 months in a patient with neuroblastoma harboring ALK F1245V, who remained on treatment for over 3.5 years due to clinical benefit (PMID: 28183697). 28183697
NTRK1 fusion hepatocellular carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion thyroid gland follicular carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion anaplastic astrocytoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic astrocytoma (NCCN.org). detail...
NTRK2 fusion sarcoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is in guidelines for patients with soft tissue sarcoma with non-specific histology and an NTRK fusion (NCCN.org). detail...
NTRK2 fusion cervical cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line therapy for patients with recurrent or metastatic cervical cancer harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK lung non-small cell carcinoma sensitive Entrectinib Preclinical - Cell line xenograft Actionable In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK were sensitive to Rozlytrek (entrectinib), resulting in inhibition of cell proliferation and complete tumor regression in cell line xenograft models (PMID: 26939704). 26939704
EML4 - ALK ALK D1203N ALK F1245V Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK D1203N and F1245V were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK L1256F Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK L1256F were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK2 fusion intrahepatic cholangiocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic intrahepatic cholangiocarcinoma harboring an NTRK fusion (NCCN.org). detail...
ROS1 - GOPC rectosigmoid cancer predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a clinical case study, Rozlytrek (entrectinib) treatment resulted in a 16% reduction of tumor burden in a patient with advanced rectosigmoid adenocarcinoma harboring ROS1-GOPC who enrolled in a Phase II trial, and the patient remained on treatment after 9 months (PMID: 33414136; NCT02568267). 33414136
NTRK1 fusion lung non-small cell carcinoma sensitive Entrectinib Phase I Actionable In a Phase I clinical trial, Rozlytrek (entrectinib) treatment resulted in partial response for more than 6 months and complete resolution of brain metastases in a non-small cell lung carcinoma patient harboring a SQSTM1-NTRK1 gene fusion (PMID: 26565381). 26565381
NTRK1 fusion lung non-small cell carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring an NTRK1 fusion (NCCN.org). detail...
NTRK1 fusion anaplastic oligodendroglioma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic oligodendroglioma (NCCN.org). detail...
NTRK2 fusion ovarian cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as systemic therapy for patients with recurrent ovarian cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion breast cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) therapy is included in guidelines for patients with recurrent or metastatic breast cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion uterine corpus sarcoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with uterine sarcoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 rearrange Advanced Solid Tumor sensitive Entrectinib Phase I Actionable In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in objective response in 75% (3/4) of patients with advanced solid tumors harboring rearrangement in NTRK1, NTRK2, or NTRK3 genes (AACR Apr 2016, Abstract # CT007). detail...
EML4 - ALK Advanced Solid Tumor sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, Rozlytrek (entrectinib) inhibited viability of transformed cells expressing EML4-ALK in culture (PMID: 33627640). 33627640
NTRK1 fusion extrahepatic bile duct carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic extrahepatic cholangiocarcinoma harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK I1171S ALK G1269A Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S and G1269A were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK1 fusion thyroid gland papillary carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion rectum cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic rectal cancer patients with an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK L1198F Advanced Solid Tumor sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, Rozlytrek (entrectinib) inhibited viability of transformed cells expressing EML4-ALK with ALK L1198F in culture (PMID: 33627640). 33627640
NTRK2 fusion stomach cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK I1171N ALK L1256F Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1256F were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
ROS1 fusion Advanced Solid Tumor predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I/II trial (STARTRK-NG), Rozlytrek (entrectinib) treatment was safe and resulted in an overall response rate (ORR) of 57.7% (15/26, 7 complete responses) with median duration of response and progression-free survival no reached in pediatric patients with CNS or extracranial solid tumors harboring fusions in NTRK1, NTRK2, NTRK3, ROS1, or ALK, ORR was 62.5% (5/8) in patients harboring ROS1 fusions (PMID: 35395680; NCT02650401). 35395680
NTRK1 fusion Erdheim-Chester disease sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring NTRK1 fusions (NCCN.org). detail...
NTRK2 fusion ampulla of Vater adenocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line therapy when the performance score is poor or as subsequent therapy for metastatic ampullary adenocarcinoma patients harboring NTRK fusions (NCCN.org). detail...
NTRK2 fusion lung non-small cell carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring an NTRK2 fusion (NCCN.org). detail...
EML4 - ALK ALK C1156Y ALK G1269A Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing ALK C1156Y and G1269A compound mutation in the context of EML4-ALK were resistant to Rozlytrek (entrectinib) in culture (PMID: 31585938). 31585938
NTRK2 fusion extrahepatic bile duct carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic extrahepatic cholangiocarcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion Erdheim-Chester disease sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring NTRK2 fusions (NCCN.org). detail...
EML4 - ALK ALK V1180L Advanced Solid Tumor sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, Rozlytrek (entrectinib) inhibited viability of transformed cells expressing EML4-ALK with ALK V1180L in culture (PMID: 33627640). 33627640
EML4 - ALK ALK L1196M Advanced Solid Tumor conflicting Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK L1196M Advanced Solid Tumor conflicting Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Rozlytrek (entrectinib), resulting in anti-proliferative activity in culture (PMID: 26939704). 26939704
NTRK1 fusion skin melanoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) therapy is included in guidelines for patients with metastatic or unresectable cutaneous melanoma harboring an NTRK fusion (NCCN.org). detail...
ROS1 positive pancreatic cancer predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in stable disease in a patient with ROS1-positive pancreatic cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)). detail...
EML4 - ALK ALK I1171N ALK L1196M Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1196M were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK1 fusion esophageal cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic esophageal cancer with an NTRK fusion (NCCN.org). detail...
NTRK2 fusion gastroesophageal junction adenocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastroesophageal junction cancer with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion Advanced Solid Tumor sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I/II trial (STARTRK-NG), Rozlytrek (entrectinib) treatment was safe and resulted in an overall response rate (ORR) of 57.7% (15/26, 7 complete responses) with median duration of response and progression-free survival no reached in pediatric patients with CNS or extracranial solid tumors harboring fusions in NTRK1, NTRK2, NTRK3, ROS1, or ALK, ORR was 60% (9/15) in patients harboring fusions in NTRK1/2/3 (PMID: 35395680; NCT02650401). 35395680
NTRK1 fusion Advanced Solid Tumor sensitive Entrectinib FDA approved Actionable In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 57% (31/54, 4 complete response, 27 partial response) in patients with NTRK1/2/3 fusion-positive advanced solid tumors, with a median duration of response of 10 months (PMID: 31838007; 2012-000148-88, NCT02097810, NCT02568267). detail... 31838007
NTRK2 fusion gastrointestinal stromal tumor sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced/metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (PMID: 34560242; ESMO.org). detail... 34560242
NTRK2 fusion gastrointestinal stromal tumor sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with unresectable gastrointestinal stromal tumor (GIST) harboring NTRK fusions (NCCN.org). detail...
NTRK1 fusion intrahepatic cholangiocarcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic intrahepatic cholangiocarcinoma harboring an NTRK fusion (NCCN.org). detail...
ALK fusion Advanced Solid Tumor sensitive Entrectinib Phase I Actionable In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in objective response in 67% (4/6) of patients with advanced solid tumors harboring rearrangement in ALK gene (AACR Apr 2016, Abstract # CT007). detail...
ALK fusion Advanced Solid Tumor sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I/II trial (STARTRK-NG), Rozlytrek (entrectinib) treatment was safe and resulted in an overall response rate (ORR) of 57.7% (15/26, 7 complete responses) with median duration of response and progression-free survival not reached in pediatric patients with CNS or extracranial solid tumors harboring fusions in NTRK1, NTRK2, NTRK3, ROS1, or ALK, ORR was 33.3% (1/3) in patients harboring ALK fusions (PMID: 35395680; NCT02650401). 35395680
ALK fusion Advanced Solid Tumor sensitive Entrectinib Phase I Actionable In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment resulted in an objective response rate of 57% (4/7) in patients with ALK rearranged advanced solid tumors that were treatment-naive, but no response (0/19) in patients who received prior Alk inhibitor treatments (PMID: 28183697). 28183697
ROS1 rearrange lung non-small cell carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring a ROS1 rearrangement, or as a next-line therapy in patients with ROS1-rearranged non-small cell lung cancer who have not received prior ROS1 inhibitor therapy (PMID: 32169226, Version Update 15 Sept 2020; ESMO.org). 32169226 detail...
ROS1 rearrange lung non-small cell carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a preferred therapy for patients with advanced or metastatic ROS1 rearrangement-positive non-small cell lung cancer (NCCN.org). detail...
ROS1 rearrange lung non-small cell carcinoma sensitive Entrectinib Phase I Actionable In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in complete response in 15% (2/13) and partial response in 77% (10/13) patients with ROS-1 rearranged non-small cell lung carcinoma that were treatment-naive (PMID: 28183697). 28183697
EML4 - NTRK3 congenital fibrosarcoma predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I/II trial, Rozlytrek (entrectinib) treatment resulted in a partial response lasting 13.8 months in a patient with infantile fibrosarcoma harboring EML4-NTRK3 (PMID: 35395680; NCT02650401). 35395680
NTRK2 fusion esophageal cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic esophageal cancer with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion thyroid gland anaplastic carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with metastatic thyroid gland anaplastic carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion Advanced Solid Tumor sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I/II trial (STARTRK-NG), Rozlytrek (entrectinib) treatment was safe and resulted in an overall response rate (ORR) of 57.7% (15/26, 7 complete responses) with median duration of response and progression-free survival no reached in pediatric patients with CNS or extracranial solid tumors harboring fusions in NTRK1, NTRK2, NTRK3, ROS1, or ALK, ORR was 60% (9/15) in patients harboring fusions in NTRK1/2/3 (PMID: 35395680; NCT02650401). 35395680
NTRK2 fusion Advanced Solid Tumor sensitive Entrectinib FDA approved Actionable In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 57% (31/54, 4 complete response, 27 partial response) in patients with NTRK1/2/3 fusion-positive advanced solid tumors, with a median duration of response of 10 months (PMID: 31838007; 2012-000148-88, NCT02097810, NCT02568267). detail... 31838007
NTRK2 fusion anaplastic oligodendroglioma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic oligodendroglioma (NCCN.org). detail...
NTRK2 fusion salivary gland cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with NTRK2 fusion-positive salivary gland tumors with distant metastases (NCCN.org). detail...
EML4 - ALK ALK L1196M ALK D1203N Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and D1203N were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
NTRK1 rearrange Advanced Solid Tumor sensitive Entrectinib Phase I Actionable In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in objective response in 75% (3/4) of patients with advanced solid tumors harboring rearrangement in NTRK1, NTRK2, or NTRK3 genes (AACR Apr 2016, Abstract # CT007). detail...
NTRK2 fusion glioblastoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent glioblastoma harboring an NTRK fusion (NCCN.org). detail...
NTRK2 fusion uterine corpus sarcoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with uterine sarcoma harboring an NTRK fusion (NCCN.org). detail...
ALK positive lung non-small cell carcinoma sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in stable disease in a patient with ALK-positive non-small cell lung carcinoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)). detail...
ROS1 rearrange Advanced Solid Tumor sensitive Entrectinib Phase I Actionable In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in an objective response rate of 86% (12/14) in patients with ROS-1 rearranged advanced solid tumors that were treatment-naive, but no response (0/6) in patients who received prior Xalkori (crizotinib) (PMID: 28183697). 28183697
ROS1 rearrange Advanced Solid Tumor sensitive Entrectinib Phase I Actionable In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in complete response in 13% (1/12) and objection response in 75% (6/8) of patients with advanced solid tumors harboring rearrangement in ROS1 gene (AACR Apr 2016, Abstract # CT007). detail...
NTRK2 fusion gallbladder cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic gallbladder cancer harboring an NTRK fusion (NCCN.org). detail...
ROS1 fusion lung non-small cell carcinoma sensitive Entrectinib FDA approved Actionable In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 77% (41/53), a median duration of response of 25 months in patients with ROS1 fusion positive non-small cell lung cancer, with median progression-free survival of 26 and 14 months for patients without (n=30) and with (n=23) CNS disease, respectively (PMID: 31838015; NCT02097810; NCT02568267). detail... 31838015
NTRK2 fusion skin melanoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) therapy is included in guidelines for patients with metastatic or unresectable cutaneous melanoma harboring an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK I1171N ALK F1174I Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and F1174I were resistant to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
ALK F1174L neuroblastoma predicted - sensitive Entrectinib Case Reports/Case Series Actionable In a Phase I/II trial, Rozlytrek (entrectinib) treatment resulted in a complete response in a patient with neuroblastoma harboring ALK F1174L (PMID: 35395680; NCT02650401). 35395680
NTRK2 fusion differentiated thyroid gland carcinoma sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for adult or pediatric patients 12 years or older with metastatic or unresectable differentiated thyroid gland carcinoma harboring NTRK fusions that have progressed on prior therapies (PMID: 31549998, PMID: 35491008; ESMO.org). detail... 35491008 31549998
NTRK1 fusion stomach cancer sensitive Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org). detail...
EML4 - ALK ALK I1171S Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK I1171N Advanced Solid Tumor resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640
EML4 - ALK ALK G1269A Advanced Solid Tumor predicted - resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Rozlytrek (entrectinib) compared to cells expressing wild-type EML4-ALK (PMID: 26939704). 26939704
EML4 - ALK ALK G1269A Advanced Solid Tumor predicted - resistant Entrectinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated resistance to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640). 33627640

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03994796 Phase II Abemaciclib GDC-0084 Entrectinib Genetic Testing in Guiding Treatment for Patients With Brain Metastases Recruiting USA 0
NCT02097810 Phase I Entrectinib Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) Completed USA 1
NCT04591431 Phase II Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) Recruiting ITA 0
NCT03330990 Phase I Entrectinib Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients Completed USA 0
NCT04632992 Phase II Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib GDC-0077 Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC) Recruiting USA 0
NCT04302025 Phase II Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer Recruiting USA 0
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Recruiting USA | ITA | FRA | ESP | DEU | BEL 10
NCT04589845 Phase II Alectinib Ado-trastuzumab emtansine Ipatasertib GDC-0077 Entrectinib Atezolizumab Idasanutlin Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 18
NCT05170204 Phase III Durvalumab Alectinib Pralsetinib Entrectinib A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Recruiting 4
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT05238831 Phase II Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole SMMART Adaptive Clinical Treatment (ACT) Trial Not yet recruiting USA 0
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 21
NCT04603807 Phase III Entrectinib Crizotinib A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Recruiting ITA | FRA | ESP 9
NCT03498521 Phase II Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) Recruiting ITA | FRA | ESP | DEU | AUT 30
NCT02587650 Phase II Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated USA 0
NCT03066661 Expanded access Entrectinib Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions No longer available USA 0
NCT02650401 Phase I Entrectinib Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) Recruiting USA | ITA | FRA | ESP | DEU | CAN 5


Additional content available in CKB BOOST